Globus Medical (GMED)
(Delayed Data from NYSE)
$70.64 USD
+0.04 (0.06%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $70.58 -0.06 (-0.08%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Income Statements
Fiscal Year end for Globus Medical, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,568 | 1,023 | 958 | 789 | 785 |
Cost Of Goods | 548 | 264 | 239 | 217 | 180 |
Gross Profit | 1,020 | 759 | 719 | 572 | 605 |
Selling & Adminstrative & Depr. & Amort Expenses | 887 | 531 | 547 | 460 | 433 |
Income After Depreciation & Amortization | 133 | 228 | 172 | 111 | 172 |
Non-Operating Income | 32 | 15 | 8 | 14 | 18 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | 165 | 243 | 180 | 126 | 190 |
Income Taxes | 43 | 53 | 31 | 24 | 35 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 123 | 190 | 149 | 102 | 155 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 123 | 190 | 149 | 102 | 155 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 359 | 302 | 245 | 175 | 224 |
Depreciation & Amortization (Cash Flow) | 225 | 74 | 73 | 63 | 52 |
Income After Depreciation & Amortization | 133 | 228 | 172 | 111 | 172 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 114.63 | 102.64 | 103.62 | 100.97 | 102.00 |
Diluted EPS Before Non-Recurring Items | 2.32 | 2.06 | 2.04 | 1.44 | 1.68 |
Diluted Net EPS (GAAP) | 1.07 | 1.85 | 1.44 | 1.01 | 1.52 |
Fiscal Year end for Globus Medical, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 629.69 | 606.67 | 616.53 | 383.64 | 291.62 |
Cost Of Goods | 260.04 | 241.49 | 265.49 | 135.39 | 76.47 |
Gross Profit | 369.65 | 365.18 | 351.05 | 248.25 | 215.14 |
SG&A, R&D, and Dept/Amort Expenses | 320.03 | 357.19 | 340.92 | 247.85 | 148.94 |
Income After SG&A, R&D, and Dept/Amort Expenses | 49.62 | 7.99 | 10.13 | 0.40 | 66.20 |
Non-Operating Income | -2.04 | -16.56 | 14.87 | 2.13 | 8.46 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 47.58 | -8.56 | 25.00 | 2.54 | 74.67 |
Income Taxes | 15.82 | -1.44 | 9.96 | 1.54 | 16.96 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 31.76 | -7.12 | 15.03 | 1.00 | 57.71 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 31.76 | -7.12 | 15.03 | 1.00 | 57.71 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 136.98 | 135.36 | 139.02 | 115.25 | 101.78 |
Diluted EPS Before Non-Recurring Items | 0.75 | 0.72 | 0.60 | 0.57 | 0.63 |
Diluted Net EPS (GAAP) | 0.23 | -0.05 | 0.01 | 0.01 | 0.57 |